CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 104 enrolled
Drug / intervention
Venetoclaxdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04267081
NCT04267081Phase 2Completed
CompareCT.gov

Two-stage, Two-arm, Open-Label Phase II Study of Venetoclax in Combination With Azacytidine in Acute Myeloid Leukemia Patients Selected Using Ex Vivo Drug Sensitivity Screening

Helsinki University Central Hospital·interventional·Posted Feb 12, 2020·Updated Sep 4, 2024

In Brief

A Phase 2 clinical trial evaluating Venetoclax for Acute Myeloid Leukemia. Completed, enrolled 104 participants across 1 site.

Detailed Summary

This is a multi center two-stage, two-arm, open label phase II study of venetoclax in combination with azacytidine in acute myeloid leukemia patients selected for therapy with ex vivo venetoclax sensitivity screening. This study will characterize the usability of ex vivo drug sensitivity testing for patient selection for selecting the responsive patients for venetoclax therapy. The exploratory study will aim to find novel combinations for overcoming resistance as well as finding/validating biomarkers for both sensitivity and resistance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesFinland
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedFeb 12, 2020
Enrollment StartFeb 12, 2020
Primary CompletionFeb 28, 2024
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 6.4 years ago

Interventions

Venetoclaxdrug

Ex vivo venetoclax sensitivity testing is used for patient selection.